Newton, MA, February 24, 2011 – Regulatory affairs professionals in the Northeastern U.S. will have to chance to hear from an industry expert about the current state of global regulations as well as what can be expected this year and beyond. On Thursday, March 24th, Helen Colquhoun, CEO of Pleiad Devices, a clinical consulting firm based in Boston, will be speaking at an event hosted by ForeignExchange Translations, Inc. It will be held at the DoubleTree Guest Suites Philadelphia West in Plymouth Meeting, Pennsylvania from 8:30 until 11:00am.
Ms. Colquhoun’s presentation is entitled, “Devices are from Mars, drugs are from Venus, but regulations are down to Earth.” It will cover the differences and similarities of global device and drug regulations, approvals in the EU, human factors testing for the FDA as well as the state of regulatory affairs in Japan. Attendees will have an opportunity to ask questions and interact with Ms. Colquhoun and other industry professionals, and leave the workshop with practical tips that they can immediately implement at their own companies.
This event is the fourth in ForeignExchange’s Multilingual Compliance Learning Series, following events in Minneapolis, Northern California and Denver. The workshop is complimentary so if you’ll be in the Philadelphia area in late March, we’d love to see you.
More information about the event can be found at: http://info.fxtrans.com/devices-are-from-mars-drugs-are-from-venus/
About Helen Coluhoun
Helen Colquhoun, MD, holds degrees in Genetics and Medicine from the University of Edinburgh and spent several years practicing clinical medicine before entering the life science industry in 1988. Helen spent seven years working with a major pharmaceutical company before setting up as an independent consultant in 1995. Since that time she has spent increasingly more time working with medical device and drug delivery companies. In 2000 she co-founded the Pleiad group of companies and is currently CEO of Pleiad Devices, a clinical research organization based in the USA and Europe that specializes in clinical research and regulatory support for medical device companies. Helen runs Pleiad’s North American operation and is based in Cambridge, Massachusetts.
About ForeignExchange Translations
ForeignExchange Translations, Inc. is redefining the delivery of foreign-language services to the medical device, biotechnology, and pharmaceutical industries. ForeignExchange’s solutions are based on its proprietary Multilingual Compliance Process, combining expert linguists, best-of-breed technology, and measurable translation quality in a robust and scalable process that can be deployed in multiple languages simultaneously. ForeignExchange provides Internet globalization, software localization, and technical translation solutions to clients such as Abbott (NYSE:ABT), Pfizer (NYSE:PFE), GlaxoSmithKline (NYSE:GSK), Baxter (NYSE:BAX), and Medtronic (NYSE:MDT). For more information, please visit www.fxtrans.com
